Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adrenal Vein Sampling International Study (AVIS Study)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gian Paolo Rossi, MD, FAHA, FACC, University Hospital Padova
ClinicalTrials.gov Identifier:
NCT01234220
First received: November 2, 2010
Last updated: January 14, 2013
Last verified: January 2013

November 2, 2010
January 14, 2013
May 2010
June 2011   (final data collection date for primary outcome measure)
Number of adrenal vein ruptures occurring during AVS [ Time Frame: January 1st 2005 - November 1st 2010 ] [ Designated as safety issue: No ]
Collection of the summary data on the way AVS is being performed throughout the world from January 1st 2005 till December 31st 2010 [ Time Frame: January 1st 2005 - December 31st 2010 ] [ Designated as safety issue: No ]

Each center will provide data on the AVS performed during the last 5 years, including:

  • the number of AVS studies;
  • information on the methodologies used for catheterization and side effects occurring during the procedure;
  • calculation of the selectivity and lateralization indexes and their cutoff values, calculation of the contralateral suppression index and its cutoff value;
  • AVS costs;
  • demographic characteristics of the patients, imaging data and biochemistry including aldosterone and cortisol levels in the infrarenal vena cava and adrenal veins;
  • final diagnosis and treatment.
Complete list of historical versions of study NCT01234220 on ClinicalTrials.gov Archive Site
  • AVS cost for the patient and the health insurance system [ Time Frame: January 1st 2005 - November 1st 2010 ] [ Designated as safety issue: No ]
    The amount in euros that the patient and the health insurance system has to pay for the AVS study will be estimated in each center.
  • number of selective AVS at right or left side [ Time Frame: January 1st 2005 - November 1st 2010 ] [ Designated as safety issue: No ]
    The number of selective AVS at right or left side will be calculated using different cutoff values for the selectivity index.
  • number of bilaterally selective AVS [ Time Frame: January 1st 2005 - November 1st 2010 ] [ Designated as safety issue: No ]
    The number of bilaterally selective AVS will be calculated using different cutoff values for the selectivity index.
  • number of lateralized AVS and number of the patients undergoing adrenalectomy [ Time Frame: January 1st 2005 - November 1st 2010 ] [ Designated as safety issue: No ]
    The number of lateralized AVS will be calculated using different cutoff values for the lateralization index.
Not Provided
Not Provided
Not Provided
 
Adrenal Vein Sampling International Study (AVIS Study)
Multicenter Study on Use and Interpretation of Adrenal Vein Sampling

The AVIS Study is a retrospective multicenter international study that aims to answer a series of questions on the use and performance of adrenal venous catheterization (AVS) for the diagnosis of primary hyperaldosteronism subtype. A questionnaire will be circulated among the centres that are internationally recognized and have published in the field of AVS and have agreed to participate in the study.

The first aim of the AVIS study is to collect summary data on how AVS is being performed throughout the world to answer the following questions:

  • How many AVS studies haw been performed yearly from 2005 to 2010 at each center?
  • How many adrenal vein ruptures occurred during the AVS at each center?Has the rate of adrenal vein rupture been steady or has it changed over the 5 years?
  • How many centers use bilaterally simultaneous and how many use sequential AVS catheterization?
  • How many radiologists perform AVS at each center?
  • How many centers use a cosyntropin stimulation during AVS?
  • What is the percentage of PA patients in whom AVS is performed?
  • How many centres calculate the selectivity index? What is the minimum cutoff used?
  • How many centers calculate the lateralization index? What is the minimum cutoff used?
  • Are the AVS studies that are not bilaterally selective used for diagnosis?
  • How many centers calculate the controlateral suppression index and what is the minimum cutoff used?
  • What is the cost of AVS for the National Health System or Insurance and for patients? The second aim of the study is to calculate the rate of AVS studies that are selective and show lateralization of aldosterone excess at each center by applying predefined set of criteria for defining selectivity and lateralization. Data on the final diagnosis of the PA subtype will be gathered and used as reference to assess the performance of AVS using receiver operating characteristic curves analysis and the Youden index to determine the optimal cutoffs. A worksheet will need to be completed providing information on the following: Demography; Date of AVS;Baseline blood pressure (BP) values and serum K+;Dynamic test during the AVS if any; plasma aldosterone and cortisol concentration in the infra-adrenal inferior vena cava and in the right and left adrenal vein; diagnosis of PA subtype; treatment (adrenalectomy or pharmacological therapy); post-treatment BP and serum K+ values; concordance/discordance between imaging (CT or RM) and AVS.

Background. AVS is recommended by the current Endocrine Society Guideline as the gold standard for the identification of the surgically curable subtype of primary aldosteronism (PA).(Funder 2008) However, consensus on the way AVS should be performed and on the interpretation of its results still lacks, as recently pointed out. (Stewart 2010, Auchus 2010) In particular, some centers use the bilateral simultaneous technique, while others perform the sequential catheterization. Moreover, some centers perform AVS during or after using ACTH stimulation, albeit with different doses, and others do not use any stimulation.(Seccia 2009) In addition, some are utilizing the absolute values of plasma cortisol and aldosterone to determinate the lateralization (Nishikawa 2007), whereas others are relying on calculation of the selectivity index to determine the collection of adrenal vein blood, followed by calculation of the and the lateralization index only if bilaterally selective samples were obtained.(Rossi 2008) Moreover, large differences in the cutoffs for establishing selectivity and lateralization exist, which have not been clarified by recent studies that rather added further complexity to this field.(Mulatero 2010) If a consistent degree of success rate can be achieved by having only one or two radiologists performing AVS at each centre, or if more radiologists can become proficient in performing the procedure and consistently achieving adequate results, also remains to be clarified. Finally, some centers perform AVS in all patients who are plausible candidates to adrenalectomy, while other submit to AVS only a small proportion of the patients (Young WJ personal communication).

Thus, it remains unclear which is the proportion of patients with PA who are offered AVS at the different centers, and how many of those who are submitted to AVS ultimately undergo adrenalectomy.

In an era of shrinking budget the issue of cost the issue of costs of the procedure also remains a relevant one when assessing the cost-effectiveness of the diagnostic work-up of PA. A preliminary survey suggests that there are huge variations across different countries in the charges for AVS to both the patients and/or the health care and insurance system.

It is likely that one of the reasons for the lack of consensus on AVS could depend on the facts that: i) no single centre as gathered a number of AVS studies large enough to warrant solid conclusions; ii) there has been no systematic survey of the AVS data that have been generated around the world in this field

Aims of the study. Based on this background, the aims of the AVIS study are those described above.

Study design. To the first aim a questionnaire will be circulated among the centers that are internationally recognized and have published in the field of AVS and have agreed to participate in the study.

The data will be collected and handled at the maximum level of confidentiality under the requirement of the Declaration of Helsinki.

Study selection criteria. Eligible centers will be identified among those that have published in the English literature on AVS or PA (reported variously as observational cohort studies, or clinical trials): Studies will be identified through computer-assisted literature searches of databases, scanning of reference lists, hand-searching of relevant journals, correspondence with authors of relevant reports and consultation with experts in the field.

The inclusion criteria will be the consent of the leading investigator to participate in the data collection.

The only exclusion criteria will be the refusal to participate in the study. The number of adhering and non-adhering centers will be recorded and mentioned in the publications.

Data collection. Data will be collected in an anonymous way on many characteristics at baseline and at subsequent surveys during follow-up. Information on categorical variables, will be systematically re-coded to ensure comparability among studies. For each individual patient, data were sought on the following outcomes: blood pressure and antihypertensive medications at follow-up post-adrenalectomy and on dates of occurrence of cardiovascular events, including non-fatal CHD; non fatal stroke; specific cause mortality (or at least fatal CDH and fatal stroke) and other cardiovascular outcomes. Being a retrospective study, precise details of the diagnostic criteria used for the definition of incident cases will be sought from each centre (as were data on the completeness of follow-up).

Data obtained from each participating study will be checked for internal consistency and any queries that might arrive will clarified with the P.I. of each centre, before harmonization to a standard format.

The content of the data will be unchanged by this process, and computer-generated detailed summary tabulations based will be reviewed and confirmed by collaborators.

Data will be stored securely and anonymously at the coordinating centre.

Statistical analysis will be performed by use of summary statistics after appropriate transformation of the variables that show a skewed distribution as PAC and PCC by means of the SPSS for Mac (vers 18.0), GaphPad and the MedCalc softwares.

Scientific Committee. The leading investigator of each centre contributing at least 50 AVS studies will be invited to participate in the scientific committee of the AVIS study and will have full access to the locked database.

Expected results. Upon completion of the first phase of the study the investigators expect to be able to gather information on the way AVS is being performed around the world and therefore to prepare a first manuscript reporting on the number of AVS per centre, the rate of adrenal vein ruptures during the procedure, the rate of use of simultaneous/sequential AVS catheterization, the number of radiologists that perform AVS and their success rate in the procedure, the rate of use of stimulation test during the perform of AVS, the percentage of PA patients to whom AVS is offered at each center, the rate of calculation of the selectivity index, the lateralization index and the contralateral suppression index and their cutoff limits, the use of AVS studies that are not bilaterally selective for diagnosis and the costs of AVS for the National Health System or Insurance and for the patients.

Upon completion of the database with the individual data the investigators expect to be able to gather > 2000 AVS studies, in a single database. After harmonization of the data, identification of the outliers and of the underlying reasons (by interaction with the leading investigator at each center), the database will be locked. The investigators will then undertake the statistical analysis, which will entail the following variables:

  • Demography (sex, age, race);
  • Baseline blood pressure (BP) and heart rate (HR) values;
  • Serum K+ before AVS;
  • Dynamic test during the AVS if any;
  • Plasma aldosterone (PAC) and cortisol concentration (PCC) in the infraadrenal inferior vena cava (IVC) and in the right (RAV) and left (LAV) adrenal vein;
  • Final diagnosis (bilateral adrenocortical hyperplasia (BAH), unilateral adrenocortical hyperplasia (UAH), aldosterone-producing adenoma (APA), bilateral APA;
  • Treatment (adrenalectomy or pharmacological therapy);
  • Post-treatment blood pressure (BP) and heart rate (HR) values;
  • Post-treatment sK+ ;
  • Diagnosis concordance/discordance between imaging (CT or RM) and AVS. Data on the demography, biochemical and hemodynamic features of the patients selected for AVS in the different continents will be obtained and information on the rate of successful catheterization will be generated. The concordance rate of imaging and AVS results will also be determined and the clinical usefulness of the AVS for establishing the indication to adrenalectomy will be ascertained in the largest database available ever.
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

All patients with Primary Aldosteronism who underwent AVS during the last 5 years in 15 worldwide centers.

Hyperaldosteronism
Not Provided
Adrenal Venous Sampling (AVS)
Patients with Primary Aldosteronism (PA) undergoing AVS to discriminate PA forms with unilateral from bilateral excess aldosterone production.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2604
November 2011
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • consent of the leading investigator to participate to the data collection

Exclusion Criteria:

  • refusal of the leading investigator to participate to the AVIS Study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Canada,   Czech Republic,   France,   Germany,   Italy,   Japan,   Netherlands,   Taiwan
 
NCT01234220
GPR-AVIS
Yes
Gian Paolo Rossi, MD, FAHA, FACC, University Hospital Padova
University Hospital Padova
Not Provided
Study Director: GianPaolo Rossi, MD, FACC Dept Clinical and Experimental Medicine (DMCS), University Hospital of Padova, Italy
University Hospital Padova
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP